Skip to main content

Table 1 Clinical characteristics and treatment responses for all patients

From: Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Variables All patients Afatinib 30 mg daily Afatinib 40 mg daily P value
N 179 102 77  
Age (year) 64.3 ± 9.4 65.7 ± 9.3 62.4 ± 9.3 0.0199
Age group:     0.0212
  < 65 years old 80 (45%) 38 (37%) 42 (55%)  
  ≥ 65 years old 99 (55%) 64 (63%) 35 (45%)  
Sex     0.0014
 Female 110 (61%) 73 (72%) 37 (48%)  
 Male 69 (39%) 29 (28%) 40 (52%)  
Smoking history:     0.9349
 Never smoker 140 (78%) 80 (78%) 60 (78%)  
 Ever smoker 39 (22%) 22 (22%) 17 (22%)  
Height (cm) 160 ± 8 159.1 ± 7.7 161.2 ± 8.4 0.0905
Weight (kg) 60 ± 11.6 58.2 ± 12.5 62.4 ± 9.9 0.0140
Body mass index (kg/m2) 23.3 ± 3.6 22.8 ± 3.7 24 ± 3.4 0.0339
Body surface area (m2) 1.6 ± 0.2 1.6 ± 0.2 1.7 ± 0.2 0.0078
Serum creatinine level 0.8 ± 0.3 0.8 ± 0.3 0.8 ± 0.3 0.4561
eCCr-CG (mL/min) a 77.1 ± 26.8 73.7 ± 25.9 81.5 ± 27.5 0.0566
eGFR-MDRD (mL/min/1.73m2) b 88.8 ± 27 88 ± 26.8 89.8 ± 27.4 0.6628
Serum albumin (mg/dL) 4.0 ± 0.5 4.0 ± 0.4 4.1 ± 0.5 0.2751
Serum glutamic oxaloacetic transaminase (U/L) 29.6 ± 22.8 31.4 ± 28.7 27.3 ± 10.4 0.1835
Serum glutamic pyruvic transaminase (U/L) 26.5 ± 25.1 26.7 ± 28.5 26.3 ± 20 0.9178
Hepatitis B: c     0.4999
 Negative 147 (84%) 86 (85%) 61 (81%)  
 Positive 29 (16%) 15 (15%) 14 (19%)  
Hepatitis C: c     0.0370
 Negative 165 (94%) 98 (97%) 67 (89%)  
 Positive 11 (6%) 3 (3%) 8 (11%)  
Old tuberculosis:     0.8901
 Negative 174 (97%) 99 (97%) 75 (97%)  
 Positive 5 (3%) 3 (3%) 2 (3%)  
Family history:     0.0859
 Negative 168 (94%) 93 (91%) 75 (97%)  
 Positive 11 (6%) 9 (9%) 2 (3%)  
Performance status while starting afatinib:     0.1024
 ECOG ≤1 146 (82%) 79 (77%) 67 (87%)  
 ECOG ≥2 33 (18%) 23 (23%) 10 (13%)  
TTF-1 stain: c     0.8901
 Positive 170 (100%) 99 (100%) 71 (100%)  
PDL-1 stain: c     0.4732
 Absence 33 (38%) 16 (34%) 17 (41%)  
 Presence 55 (63%) 31 (66%) 24 (59%)  
EGFR gene mutation site: d     
 Exon 19 95 (53%) 60 (59%) 35 (45%) 0.0760
 Exon 21 85 (47%) 42 (41%) 43 (56%) 0.0517
TNM staging:     
 N2–3 112 (63%) 67 (66%) 45 (58%) 0.3214
 M1a-c 179 (100%) 102 (100%) 77 (100%) 0.5136
Number of metastatic sites/organs (1–2 vs. > 2)     0.2360
 1 site 64 (36%) 41 (40%) 23 (30%)  
 2 sites 69 (39%) 39 (38%) 30 (39%)  
  ≥ 3 sites 46 (26%) 22 (22%) 24 (31%)  
Metastatic site/organ on initial diagnosis
 Brain 53 (30%) 21 (21%) 32 (42%) 0.0023
 Lung 79 (44%) 40 (39%) 39 (51%) 0.1272
 Pleura (or with pleural effusion) 80 (45%) 47 (46%) 33 (43%) 0.6678
 Bone 99 (55%) 59 (58%) 40 (52%) 0.4322
 Liver 22 (12%) 15 (15%) 7 (9%) 0.2573
 Adrenal 16 (9%) 8 (8%) 8 (10%) 0.5544
 Other sites 11 (6%) 5 (5%) 6 (8%) 0.4253
  1. Data are presented in mean ± standard deviation (SD) or n (%)
  2. aeCCr-CG estimated creatinine clearance rate using Cockcroft-Gault equation, while CrCl was multiplied by 0.85 for female patients
  3. b eGFR-MDRD estimated glomerular filtration rate using Modification of Diet in Renal Disease equation. GFR was multiplied by 0.742 and 1.212 for female patients and African-American, respectively
  4. cIncluding missing values
  5. dA patient had EGFR mutation in both exon 19 and exon 21